Table 4.
Multiple Variable Logistic Regression Analysis for Predictors of Renal Failure through 144 Weeks of ART.
| Weeks of ART (Complete Cases/Multiple Imputation) | Explanatory Variable | Complete Cases | Multiple Imputation | ||
|---|---|---|---|---|---|
| aOR (95% CI) | P Value | aOR (95% CI) | P Value | ||
| 24 (3806/8303) | Males | 0.86 (0.66-1.13) | .29 | 0.91 (0.59-1.4) | .61 |
| Age, years | 1.04 (1.02-1.05) | <.001 | 1.01 (0.97-1.05) | .52 | |
| WHO stage 3 and 4 | 1.23 (0.96-1.59) | .11 | 0.9 (0.49-1.64) | .66 | |
| CD4 cells/mm3 ≤100 | 1.05 (0.8-1.38) | .71 | 1.17 (0.58-2.36) | .59 | |
| VL >10 000 copies/mL | 1.3 (1-1.67) | .05 | 0.99 (0.74-1.32) | .92 | |
| HBV positive | 1.22 (0.91-1.63) | .19 | 0.95 (0.69-1.31) | .74 | |
| Baseline GFR | 1 (1-1) | .10 | 1 (1-1) | .68 | |
| TDF exposure | 2.34 (1.75-3.13) | <.001 | 1.47 (1.16-1.87) | <.001 | |
| 48 (3784/8303) | Males | 0.92 (0.75-1.12) | .41 | 0.91 (0.67-1.25) | .52 |
| Age, years | 1.04 (1.03-1.05) | <.001 | 1.01 (0.96-1.06) | .55 | |
| WHO stage 3 and 4 | 0.78 (0.64-0.96) | .02 | 0.83 (0.64-1.09) | .16 | |
| CD4 cells/mm3 ≤100 | 0.93 (0.76-1.13) | .46 | 1.08 (0.77-1.51) | .60 | |
| VL >10 000 copies/mL | 0.88 (0.72-1.07) | .19 | 0.88 (0.59-1.31) | .45 | |
| HBV positive | 1.2 (0.95-1.53) | .12 | 1.12 (0.83-1.5) | .41 | |
| Baseline GFR | 1 (1-1) | .12 | 1 (1-1) | .57 | |
| TDF exposure | 1.03 (0.84-1.25) | .79 | 1.25 (0.9-1.75) | .15 | |
| 96 (2802/8303) | Males | 1.01 (0.78-1.31) | .95 | 1.1 (0.48-2.51) | .76 |
| Age, years | 1.01 (1-1.02) | .14 | 1 (0.96-1.05) | .76 | |
| WHO stage 3 and 4 | 0.89 (0.69-1.16) | .40 | 0.94 (0.35-2.48) | .87 | |
| CD4 cells/mm3 ≤100 | 1.18 (0.89-1.56) | .26 | 1.1 (0.18-6.68) | .90 | |
| VL >10 000 copies/mL | 1.02 (0.79-1.34) | .86 | 1.4 (0.66-2.97) | .29 | |
| HBV positive | 1.49 (1.16-1.93) | <.001 | 0.86 (0.32-2.34) | .70 | |
| Baseline GFR | 1 (1-1.01) | .10 | 1 (1-1) | .99 | |
| TDF exposure | 5.42 (3.38-8.7) | <.001 | 0.77 (0.39-1.55) | .37 | |
| 144 (3244/8303) | Males | 1.04 (0.85-1.27) | .68 | 1.08 (0.56-2.1) | .77 |
| Age, years | 1.01 (1-1.02) | .17 | 0.98 (0.92-1.06) | .55 | |
| WHO stage 3 and 4 | 1.33 (1.1-1.61) | <.001 | 1.35 (0.52-3.51) | .43 | |
| CD4 cells/mm3 ≤100 | 1.06 (0.87-1.3) | .56 | 1.24 (0.59-2.62) | .48 | |
| VL >10 000 copies/mL | 0.92 (0.75-1.12) | .41 | 1.1 (0.42-2.87) | .79 | |
| HBV positive | 1.35 (1.1-1.66) | <.001 | 1.18 (0.88-1.58) | .23 | |
| Baseline GFR | 1 (1-1) | .10 | 1 (0.99-1.01) | .47 | |
| TDF exposure | 4.71 (3.72-5.97) | <.001 | 2.36 (1.28-4.34) | .02 | |
Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; GFR, glomerular filtration rate; HBV, hepatitis B virus; TDF, tenofovir disoproxil fumarate; VL, viral load; WHO, World Health Organization.